- AdventHealth
On October 3, 2022, an AdventHealth Heart, Lung and Vascular Institute (HLVI) team under the leadership of cardiothoracic surgeon Ahmad Zeeshan, MD, became the first in Florida to successfully implant the Thoraflex™ Hybrid Frozen Elephant Trunk (FET) device in a 73-year-old patient with a complex aortic arch dissection that involved the aortic root, ascending aorta and the aortic arch.
Terumo Aortic’s Thoraflex™ Hybrid device is indicated for the surgical treatment of complex aortic aneurysms and dissections. It has been used in Europe for a while, and after the U.S. Food and Drug Administration’s (FDA) approval in April 2022, the device is now commercially available in the U.S. It is made of a polyester graft section that reinforces a weakened section of the aorta. A connected stented section (nitinol wire frame on polyester graft material) keeps the descending aorta open and allows better blood flow through the true lumen. The polyester graft and stented portions are coated with a bovine gelatin to seal the implant and prevent unnecessary blood loss from the graft pores. The gelatin-coated woven polyester graft replaces the remaining diseased aorta.
“This first-of-its-kind surgical device significantly enhances treatment of aortic arch pathology,” explains Dr. Zeeshan. “Complex aortic arch reconstruction is an unusual surgical procedure that requires placing the patient under deep hypothermic circulatory arrest. Because of its hybrid design, the Thoraflex™ device decreases the duration of implant time; hence, the duration of deep hypothermic circulatory arrest time, resulting in fewer complications. Additionally, the device facilitates stage 2 of the elephant trunk procedure when needed.”
The results of a multi-center U.S. clinical trial were recently published in the Journal of Thoracic and Cardiovascular Surgery. The study found that use of the Thoraflex™ Hybrid device resulted in 81% freedom from major adverse events at one year.
“This is an exciting milestone,” says Dr. Zeeshan. “Prior to the availability of the Thoraflex™ Hybrid device at AdventHealth HLVI, Central Florida patients had to be referred out for complex aortic arch surgery. Now, they can receive this care closer to home.”
AdventHealth HLVI remains committed to combining technical ability with the latest technology to bring advanced cardiovascular care to patients.
Recent News
Kidney-tumor patients have an innovative new treatment option, first performed recently by a surgical team at AdventHealth Celebration.
Test Apple Podcast
As the Official Healthcare Provider of the 2024 NASCAR Chicago Street Race, we’re thrilled to support such a memorable experience with this amazing community.
The innovative new treatment targets and destroys tumors using sound beams, noninvasively and without the need for needles and incisions.
A summary of the article goes here. A summary of the article goes here. A summary of the article goes here. A summary of the article goes here.
The innovative new treatment targets and destroys tumors using sound beams, noninvasively and without the need for needles and incisions.
Dr. Corbin on the gut microbiome research study
A genetic test, originally conducted to help better understand her daughter's diagnosis, revealed Samantha Arceneaux carries a genetic variant that virtually guarantees she will develop an aggressive...
Under the leadership of investigator Guru Sonpavde, MD, AdventHealth’s Clinical Research Unit (CRU), a collaborative between the AdventHealth Cancer Institute and AdventHealth Research Institute, is...
The AdventHealth Research Institute recently launched two new clinical studies to better understand and address the needs of healthcare employees who work night shifts.
In January 2024, AdventHealth Celebration neurotologist Michael Seidman, MD, FACS, became the first in Florida and the Southeast to complete a robotics-assisted cochlear implant procedure using the...
The CheckMate 901 Phase III clinical trial results, recently published in the New England Journal of Medicine, found that combining the programmed death 1 (PD1) inhibitor immunotherapy nivolumab with...